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Introduction: There have been concerns with the availability and affordability of EMA’s
recently approved medicines with a conditional approval in Korea. This needs to be
addressed to provide future guidance to the authorities in Korea.
Objective: Compare the availability and affordability of medicines with a conditional
approval by the European Medicines Agency (EMA) among 12 countries (United States,
United Kingdom, France, Germany, Switzerland, Italy, Japan, Canada, Taiwan, Australia,
New Zealand, and Korea) in light of access to medicine concerns in Korea.
Methods: Thirteen medicines were selected and compared in terms of their availability
and affordability across 12 countries. Approval rate for the selected medicines and time
lag to approval on the basis of EMA’s approval dates were calculated. Reimbursement
status and prices were compared as proxies of affordability.
Results: The average approval rate was 31.9% for the selected medicines for all
countries outside the EU countries. The highest rate was in United States (69.2%)
followed by Korea and Switzerland (46.5%). An average of 238 days was taken among
the countries for approval. The United States (median: −355 days) was the country
where the medicines were most rapidly approved. Korea (152 days) ranked the fifth
most rapidly approving country. An average listing or reimbursement rate for all countries
was 54.1%. The United States ranked 100% for the listing of their approved medicines
followed by Germany (92.3%). Korea (66.7%) ranked eighth. Price dispersion ranged
from 1.1 to 3.1. Korean prices of the selected medicines were found to be neither high
nor low when compared to other countries.
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Conclusion: Korea was found to be a country where marketing authorization for more
medicines tended to be made and subsequent reimbursement and pricing were not
rigid even generous compared to other Asian-pacific countries. Korean drug benefit
policies for listing and pricing did not appear to hinder access to medicines even with a
conditional approval in comparison with others.
Keywords: access, affordability, conditional approval, EMA, Korea, reimbursement
INTRODUCTION
Unlike resource limited countries, access to essential medicines
is well-established in high income countries (Hogerzeil, 2004).
The concept of essential medicines for high income countries
is though still controversial (Hogerzeil, 2004; Duong et al.,
2015). However, there have been good examples such as the
‘Wise List’ in Stockholm County Council, Sweden, with high
adherence to a limited list of medicines that cover over 90%
of the needs of patients in ambulatory care (Gustafsson et al.,
2011; Bjorkhem-Bergman et al., 2013; Eriksen et al., 2017). These
high adherence rates in Sweden have been achieved through the
introduction of robust processes for medicine selection coupled
with a comprehensive communication program (Godman et al.,
2009; Bjorkhem-Bergman et al., 2013; Eriksen et al., 2017, 2018).
Similar examples exist in other countries (Bjorkhem-Bergman
et al., 2013). Having said this, providing medicines which meet
the priority needs of the community through reliable health
systems was a key principal for access to medicines (Hogerzeil,
2004).
Access to medicines can be assessed by their availability
and aﬀordability (World Health Organization (WHO), 2010).
Availability refers to marketing authorization, available stocks,
and distribution (World Health Organization (WHO), 2011a;
Erginel, 2014); with aﬀordability closely related to the price of
medicines and economic subsidies of healthcare systems. More
speciﬁcally, copayments for medicines directly aﬀects the use of
medicines (Godman et al., 2014; Putrik et al., 2014; Simoens
and Sinnaeve, 2014; Kostic et al., 2017), with the degree of
coverage for pharmaceuticals depending on the country, the types
of medicines and the socioeconomic status of the beneﬁciaries
(Niëns et al., 2012; Niëns and Brouer, 2013).
Korea is a country that achieved universal health coverage
in 1989. As the growth of pharmaceutical expenditure in
Korea has been greater than other health expenditures (16.3 vs.
15.2% as of 2006), and the portion of drug spending to total
health expenditures was greater (21.4% as of 2015) compared
to OECD countries (16.3%) (Organisation for Economic Co-
operation and Development [OECD], 2012; Ministry of Health
and Welfare (MOHW), 2015), policy makers and regulators
in Korea have mainly focused on drug cost containment
policies in recent years. As part of this process, a positive list
system (PLS) was introduced in 2007 to select medicines to
be reimbursed based on their cost-eﬀectiveness to the National
Health Insurance (NHI). Since the introduction of the PLS,
non-reimbursable medicines have been oﬃcially allowed to
be prescribed with no restrictions but associated with co-
payments. In particular, high cost medicines, which hardly met
the agreed incremental cost-eﬀectiveness ratio (ICER) threshold
were not reimbursed but could still be prescribed for treatment
with the costs charged to the patient. As a result, issues
of patients’ access to medicines have been raised especially
for high cost medicines such as anticancer agents and those
for rare diseases where co-payments are an issue (Korean
Research-based Pharma Industry Association [KRPIA], 2016).
This controversy has inﬂuenced Korean drug policy with the
government now taking a more liberal attitude towards selecting
medicines for reimbursement through measures including a
ﬂexible application of ICER thresholds, the exemption of cost-
eﬀectiveness appraisals for some medicines, exemptions of price
negotiations for somemedicines as well as the introduction of risk
sharing arrangements (Ministry of Health and Welfare in Korea
(MOHW), 2013; Ministry of Health Welfare in Korea (MOHW),
2014). Despite these measures, patients’ advocacy groups and
pharmaceutical companies are still appealing to switch back to
the negative list system under the name of patient’s rights of
access to medicines (Korean Research-based Pharma Industry
Association [KRPIA], 2016).
For the interest on public health, conditional approval can
be available when the beneﬁt of the immediate availability of
medicines outweighs the risk with less comprehensive data than is
normally required based on marketing authorization guidelines.
The European Medicines Agency (EMA) grants conditional
approval for medicines that are aimed at treating, preventing, or
diagnosing, seriously debilitating or life-threatening diseases or
intended for use in emergency situations or designated as orphan
medicines (European Medicines Agency [EMA], 2017, 2018b).
Consequently, medicines with a conditional approval were seen
as urgently addressing the unmet needs of patients and/or the
treatment of severe conditions. These medicines were selected as
a subject to address access to medicine issues in Korea given the
ongoing controversies that exist in Korea.
In view of this, the purpose of this study is to explore
the availability and aﬀordability of EMA’s recently approved
medicines with a conditional approval in Korea by comparing
the situation in Korea with 11 other countries that are typically
referenced by Korea. Subsequently, to review the ﬁndings and
their implications for the Korean pharmaceutical pricing and
reimbursement system in light of their access to medicines.
Having said this, there have been concerns with the conditional
authorization system in Europe (Banzi et al., 2015). The
conditional approval system is diﬀerent to the recently discussed
EMA Adaptive Pathways process intended to also accelerate the
uptake of new innovative medicines into routine clinical care
in Europe, where there have also been concerns (Ermisch et al.,
2016; Vella Bonanno et al., 2017).
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MATERIALS AND METHODS
Study Subjects
Considering the severity of diseases and importance of access to
new innovative medicines that appear to address unmet need
in these critical areas, we collected the list of medicines with
conditional approval by EMA from 2014 to 2017 (European
Medicines Agency [EMA], 2018a). If these medicines are
approved and reimbursed given typically limited clinical data,
this would suggest high levels of availability and aﬀordability of
new premium priced medicines. Accordingly, a total 14 drugs
were selected for this study, and of these all were designated as
orphan drugs as well-except for the Pandemic Flu vaccine. We
subsequently excluded the Pandemic Flu Vaccine because it is
not part of the NHS system in some countries, i.e., the inﬂuenza
vaccine was provided via the National Immunization Program,
which is funded by a general tax in Korea, Japan and Taiwan
(Nakatani and Sano, 2002; Lee and Choi, 2008; Tang et al., 2011;
Saitoh and Okabe, 2012), and it is currently not reimbursed
among a high number of countries involved in this research. This
left 13 medicines for analysis.
Country Comparison
Access to the selected medicines in 12 countries were compared.
These countries were the United States, United Kingdom, France,
Germany, Switzerland, Italy, Japan, Canada, Taiwan, Australia,
New Zealand, and Korea. They were speciﬁcally chosen as most
of them are oﬃcially referenced by the Korean reimbursement
and pricing authorities. In addition, all countries except the
United States ensure access to medicines through their national
healthcare systems.
We searched oﬃcial websites of each country to collect
information on market approval, reimbursement status and the
ﬁxed prices of the selected medicines prior to any conﬁdential
discount.
Availability: Approval and Time Lag to
Approval
Marketing approval is the ﬁrst step to launching new medicines
across countries. Without market authorization, medicines are
not available in a country. For the EU (European Union) member
countries, approval of medicines is typically made by the EMA
through a centralized process. All other countries have their own
authorities for the marketing authorization of medicines such
as the Food and Drug Administration (FDA) for United States
and the Ministry of Food, Drug and Safety (MFDS) for Korea.
We checked the approval rate of the selected medicines for all
countries except European countries.
We also checked the moment of licensing in other than
EU countries and calculated the time lag to approval on the
basis of EMA’s approval date. Although market authorization
applications are initiated by manufacturers, time lag to approval
represents the delay of the availability of these new medicines
across countries.
Affordability: Reimbursement Status and
Prices
Reimbursement status and prices of the selected medicines were
considered as proxies of aﬀordability. However, we are aware
that the diﬀerent countries have diﬀerent processes and systems
for the pricing and reimbursement of medicines including
whether reimbursed prices are based on the perceived level
BOX 1 | Data source.
Country Source Type of prices
United Kingdom MIMS Ex-factory pharmacy price (Patented Medicine Prices Review Board in Canada [PMPRB], 2017)
United States Redbook Ex-factory pharmacy price (Patented Medicine Prices Review Board in Canada [PMPRB], 2017)
FSS Contract price for qualified government (Organisation for Economic Co-operation and Development
[OECD], 2008)
France VIDAL Ex-factory wholesale price (Patented Medicine Prices Review Board in Canada [PMPRB], 2017)
Italy www.codifa.it (L’Informatore
Farmaceutico)
Ex-factory wholesale price (Patented Medicine Prices Review Board in Canada [PMPRB], 2017)
Ex-factory hospital price for hospital drugs (Patented Medicine Prices Review Board in Canada
[PMPRB], 2017)
Germany Rote-Liste Ex-factory wholesale price (Patented Medicine Prices Review Board in Canada [PMPRB], 2015)
Swiss Federal Office for Public
Health
Ex-factory wholesale price (Patented Medicine Prices Review Board in Canada [PMPRB], 2017)
Canada Ontario drug benefit
formulary
Ex-factory price (Ontrario Ministry of Health and Long-term care in Canada, 2018)
Australia PBS Dispensed price for maximum amount (Australian Government Department of Health, 2018)
New Zealand Pharmac Ex-factory price (Pharmaceutical Management Agency in New Zealand [PHARMAC], 2018)
Japan MHLW Ex-factory pharmacy price (The Federation of Japan Pharmaceutical Wholesalers Association
[JPWA], 2014)
Taiwan NHIA Public Price
Korea HIRA Ex-factory pharmacy price
MIMS, Monthly Index of Medical Specialties; FSS, Federal supply schedule; PBS, Pharmaceutical Benefits Scheme; Pharmac, Pharmaceutical management agency;
MHLW, Ministry of Health, Labour and Welfare; NHIA, National Health Insurance Administration; HIRA, Health Insurance Review & Assessment Service.
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of innovation versus current standards or economic measures
such as ICERs with or without agreed threshold levels (Paris
and Belloni, 2013; Godman et al., 2015, 2016; World Health
Organization (WHO), 2015). Whether the medicines were listed
by national healthcare system was checked from the public
information sources (see Box 1). For the United States, we
checked both the Redbook and the Federal Supply Schedule
(FSS).
For price comparisons, we used public prices for reimbursed
medicines. Public prices do not generally reﬂect eﬀective prices
since substantial rebates or discounts are being oﬀered to
insurers in many countries to enhance reimbursement for new
premium priced medicines. These conﬁdential arrangements
between manufacturers and payers are increasingly practiced
(Vogler et al., 2012; Ferrario and Kanavos, 2013, 2015;
Ferrario et al., 2017; Pauwels et al., 2017). However, published
prices are the only publicly available information for price
comparisons. We compared prices of the selected medicines
with this limitation and careful interpretation. Each country
publishes prices online and types of prices are diﬀerent,
for examples, ex-factory prices, ex-factory wholesale price
and ex-factory pharmacy price. Types of price and the
source of price information for each country are shown
in Box 1.
RESULTS
Table 1 shows the brand-name with active pharmaceutical
ingredients and the main indications of the 13 selected
medicines approved by EMA during 2014–2017. As of March
16, 2018, the average number of countries in which the
selected medicines were licensed was three out of eight (except
four European countries). Blinatumomab (BlincytoTM) and
Ixazomib (NinlaroTM) had been approved in six countries while
HoloclarTM, TranslarnaTM (Ataluren), and ZalmoxisTM were not
yet approved. Blinatumomab was listed in eight countries while
ZalmoxisTM was not yet reimbursed.
Approvals by County
On average, there was a 31.9% approval rate for the 13 medicines
for all countries except the EU countries. The approval status
for each country is depicted in Figure 1. As EMA approval
was a reference, all the included EU countries had approval
for the 13 medicines while Switzerland had approved only
six medicines. The highest rate of approval was shown in
United States (69.2%, 9 out of 13) followed by Korea (46.2%)
and Switzerland (46.2%, 6 out of 13 products). Taiwan and
New Zealand showed the lowest approval rate of 15.4% (2 out
of 13 products). Among Asia paciﬁc countries, Korea was
a country where more medicines were available than other
countries.
Time Lag to Approval
As shown in Figure 2, the time lag to approval was calculated
on the basis of EMA’s approval date and compared among the
eight other target countries. An average of 238 days (median:
+120 days) were taken among the countries for approval. The
United States (median: −355 days) was the country where all
medicines were most rapidly approved followed by Canada
(median:+29 days) and Japan (median:+98 days).
Korea (median: +152 days) was ranked the ﬁfth most rapidly
approving country. Unlike EU countries, Switzerland had taken
a relatively long time for approval. Taiwan and New Zealand
showed 603 and 614.5 days respectively for the time lag
from the EMA. Korea, Japan, and Autralia had the greatest
variations between maximum and minimum values while the
United States received FDA’s approval before the EMA’s approval
date. Unlike the approval rate, Korea took a relatively long
time to approve the selected medicines compared to Japan and
Australia.
TABLE 1 | Basic information of the selected medicines.
Brandname API Main indication Approval date(EMA) No. of authorized
countriesa
No. of reimbursed
countriesb
BavencioTM Avelumab MCC 18 September 2017 9 (5) 5 (41.7%)
BlincytoTM Blinatumomab ALL 23 November 2015 10 (6) 8 (66.7%)
CometriqTM Cabozantinib Medullary thyroid carcinoma 21 March 2014 8 (4) 6 (50.0%)
DeltybaTM Delamanid MDR-TB 23 April 2014 6 (2) 6 (50.0%)
HoloclarTM human corneal cells with stem cells limbal stem cell deficiency 17 February 2015 4 (0) 2 (16.7%)
LartruvoTM Olaratumab soft tissue sarcoma 9 November 2016 8 (4) 6 (50.0%)
NatparTM Parathyroid hormone chronic hypoparathyroidism 24 April 2017 5 (1) 3 (25.0%)
NinlaroTM Ixazomib multiple myeloma 21 November 2016 10 (6) 6 (50.0%)
OcalivaTM Obeticholic acid primary biliary cholangitis 12 December 2016 5 (1) 5 (41.7%)
SirturoTM Bedaquiline MDR-TB 5 March 2014 9 (5) 6 (50.0%)
TranslarnaTM Ataluren Duchenne muscular dystrophy 31 July 2014 4 (0) 4 (33.3%)
VenclyxtoTM Venetoclax CLL 5 December 2016 9 (5) 5 (41.7%)
ZalmoxisTM Allogeneic T cells HSCT 18 Auguest 2016 4 (0) 0 (0.0%)
MDR-TB, multidrug resistant tuberculosis; ALL, acute lymphoblastic leukemia; HSCT, haploidentical haematopoietic stem cell transplantation; CLL, chronic lymphocytic
leukaemia; MCC, metastatic Merkel cell carcinoma. aMaximum number of countries is 12 and 8 between brackets, which excluded EU countries. bNumber of countries
where the selected medicines were reimbursed, % out of 12 in brackets.
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FIGURE 1 | Number of approved medicines and approval rates by country. NB: Brackets = % of approved medicines out of 13.
FIGURE 2 | Box-plot of time lag to approval on the basis of EMA (Maximum, Median, Minimum values).
Reimbursement Status
Among the approved medicines, an average reimbursement
rate for the 12 countries was 54.4%. Although all medicines
were approved in European countries, listing (reimbursement)
rates varied greatly across the countries as shown in Figure 3.
Germany (92.3% of the 13 medicines) showed a relatively
high rate of reimbursement followed by the United Kingdom
(76.9%) whereas Switzerland, whilst in Europe but not part of
the EU, only reimbursed ﬁve out of six approved medicines
(83.3%).
Overall, the United States ranked 100% of listing of the nine
approvedmedicines based on the Redbook. However, eight out of
nine medicines were listed in the FSS (88.9%). Germany (92.3%,
12 out of 13) ranked 2nd followed by Switzerland (83.3%, ﬁve
out of six), United Kingdom (76.9%, 10 out of 13), Japan (75.0%,
three out of four), as well as France and Italy (69.2%, 9 out of 13).
Korea ranked eighth with a listing rate of 66.7% (of 6) followed by
Australia (25.0% of 4). Canada, Taiwan, and New Zealand listed
none of the medicines. Within Asia-Paciﬁc region, Japan showed
the highest rate of reimbursement followed by Korea.
Price Comparisons
Figure 4 depicts the prices of each medicine for all the
countries. Prices were adjusted with Purchasing Power Parity
(PPP_USD). Although the types of prices diﬀered by country
and direct comparison was controversial, it was found that price
dispersion was broad with some medicines such as Cabozantinib,
Avelumab, Olaratumab and Obeticholic acid. However, there was
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FIGURE 3 | Number of reimbursed medicines and listing rate by country. NB: Redbook was referenced for the United States and brackets = % of reimbursed (listed)
medicines out of those approved.
FIGURE 4 | Prices of the medicines with a conditional approval (PPP_USD, Maximum, Median, Minimum values). Holoclar was not depicted as German price was
unidentified. Its price of 120,396 (PPP) in Italy was not depicted.
limited price dispersion with Ataluren. The price dispersion,
calculated by the maximum price divided by the minimum
price, ranged from 1.1 to 3.1. Even in the same country such
as the United States, the prices from the Redbook and FSS
diﬀered. On average, the Redbook prices (AWPs) were 1.7
times [1.1∼1.8] higher than the FSS prices. Price dispersion
and the number of listed countries were signiﬁcantly correlated
(ρ = 0.704, p = 0.0072). Thus, the more countries the drug is
listed, the greater the diﬀerence in drug prices. This proves that
the one price policy of drug companies is not typically applied
empirically.
Table 2 shows the prices of four medicines listed in Korea
compared to the other countries. Although direct comparisons of
prices with diﬀerent attributes should be done carefully, the price
level of Korea was estimated with this limitation. The prices of
Blinatumomab ranged from 0.8 to 1.6 times of the Korean price
and those of Olaratumab ranged 1.3 to 2.4 times. For bedaquiline
(0.8∼1.1 times) and delamanid (0.6∼1.4 times), Korean prices
were found to be relatively high in consideration of compared
countries’ GDP level.
DISCUSSION
Access to medicines has been a common issue for among low
and middle-income countries (Cameron et al., 2009). Even high
income countries are now struggling to fund new premium
priced medicines whilst maintaining universal access, which has
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TABLE 2 | International price comparison of Korea’s reimbursement drug (USD PPP).
Countries Bedaquiline Delamanid Blinatumomab Olaratumab Reference
US Redbook 191 (1.1) – 4,449 (1.6) 57.8 (2.4) Ex-factory pharmacy price
FSS – – 2,385 (0.8) 36.0 (1.5) Contact price for government
UK 141 (0.8) 37 (0.8) 2,867 (1.0) 54.0 (2.2) Ex-factory pharmacy price
France – 37 (0.8) 3,293 (1.2) – Ex-factory wholesale price
Italy 150 (0.8) 39 (0.9) 3,582 (1.3) 34.9 (1.4) Ex-factory wholesale price
Swiss – – 2,321 (0.8) – Ex-factory wholesale price
Germany 180 (1.0) 38 (0.8) 2,864 (1.0) 32.6 (1.3) Ex-factory wholesale price
Japan – 62 (1.4) – – Ex-factory pharmacy price
Australia – – 2,724 (1.0) – Dispensed price for max amount
Korea 180 (1) 45 (1) 2,822 (1) 24.2 (1) Ex-factory pharmacy price
resulted in newmodels to improve their managed entry (Godman
et al., 2012, 2015, 2016; Malmstrom et al., 2013; Paris and Belloni,
2013).
This study explored access to medicines, particularly issues
surrounding the Korean context in terms of the availability and
aﬀordability of recently approved medicines in areas of high
unmet need. Thirteen medicines with conditional approval in
the EU were selected for their urgency and necessity to address
patients’ unmet needs, with a 37.5% approval rate among eight
countries excluding the four European countries. An average
time lag to approval was 238 days from EMA’s approval date.
The United States with a 69.2% approval rate was always a
country that manufacturers attempted to obtain approval before
EMA approval. Among the 13 EMA approved medicines, an
average reimbursement rate for the 12 countries was 54.4%. Some
countries including Australia, Canada, Taiwan, andNewZealand,
tended to be laggards to approve and reimburse the selected
medicines.
The range of prices was found to be broad among
most of the researched medicines. This is contrary
to a one price policy as a global pricing strategy
(World Health Organization (WHO), 2011b; Young et al.,
2017), which has been often claimed by global pharmaceutical
companies. However, some publications have shown
considerable variation in the prices of patented medicines
across countries (Leopold et al., 2013; Vogler et al., 2015), similar
to our ﬁndings, with the price of medicines varying depending
on issues such as national reimbursement policies and economic
levels (Garau et al., 2011; Paris and Belloni, 2013; Towse et al.,
2015; Godman et al., 2016). In addition, as mentioned, we are
seeing the rise in managed entry agreements across countries
to increase access to new medicines, which often contain
conﬁdential discounts (Vogler et al., 2012; Ferrario and Kanavos,
2013, 2015; Godman et al., 2016; Ferrario et al., 2017; Pauwels
et al., 2017) making price comparisons diﬃcult.
Encouragingly, Korea ranked second in the approval rate
of 46.5% excluding EU countries and ﬁfth in the time lag of
152 days [−20∼1,285]. The reimbursement rate was 66.7% of
the approved medicines, with the prices of the selected medicines
neither high nor low in comparison with the other countries.
We are aware this study has limitations. Firstly, we selected
medicines with a conditional approval. These medicines were
considered exceptional compared to others, which normally
go through standard procedures of marketing approval and
reimbursement appraisal. As we explored the states of approval
and reimbursement of these medicines across the board, it may
be diﬃcult to generalize the results to other medicines. Secondly,
published price information diﬀered across the countries and
it can be problematic to directly compare them. However,
we could not adjust prices for comparison especially as some
countries adopt risk sharing schemes or clawback systems
for new medicines and published prices do not reﬂect these
adjusted prices (Ferrario and Kanavos, 2013; Ferrario et al.,
2017). In view of this, we had to approximately compare
Korean prices with others to ﬁnd some implications. In addition,
we did not consider other funds besides the pharmaceutical
beneﬁt schemes, e.g., Blinatumomab was not covered by Ontario
Drug Beneﬁt formulary although it did through NDFP (New
Drug Fund Program) (Cancer Care Ontario in Canada (CCO),
2017).
Nevertheless, this study demonstrated contradictory results
to pharmaceutical company’s one pricing strategy (World
Health Organization (WHO), 2011b) since most of the studied
medicines showed a wide range of price distribution except
Ataluren. Our study though reconﬁrmed the strategy that
pharmaceutical companies try to delay the launch of their
new medicine in countries with traditionally low prices
or even not market at all in countries that are referenced
by other countries with larger markets (Leopold et al.,
2013; Vogler et al., 2015; Young et al., 2017), exacerbated
particularly in Europe by extensive reference pricing across
countries (Leopold et al., 2012). The United States showed
100% reimbursement of approved medicines and the
highest prices while Taiwan and New Zealand were delayed
in both their approval and reimbursement of the selected
medicines.
As a result, the availability and aﬀordability of the selected
medicines featured geographically diﬀerent aspects. Asia-
paciﬁc countries that are mostly small markets, or try to
attain lower prices, were delayed in their approval and
reimbursement rates for these selected medicines compared
to other continents. However, Korea performed better than other
selected Asian-Paciﬁc countries for these medicine, which is
encouraging given ongoing concerns.
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CONCLUSION
Korea was found to be a country where marketing
authorization for more these selected medicines with EMA
conditional reimbursement tended to be made, and subsequent
reimbursement and pricing were not rigid even generous
compared to other Asian-paciﬁc countries. As a result,
contrasting with the arguments of patient’s advocacy groups and
pharmaceutical companies in Korea (Korean Research-based
Pharma Industry Association [KRPIA], 2016). Consequently,
Korean drug beneﬁt policies for listing and pricing did not
appear to hinder access to medicines even with a conditional
approval in comparison with other countries. This is to be
encouraged.
AUTHOR CONTRIBUTIONS
HK and H-YK developed the concept of the paper and undertook
the analysis. All the authors were involved with developing and
reﬁning the manuscript and approved the ﬁnal draft before
submission.
REFERENCES
Australian Government Department of Health (2018). Elements of PBS DPMQ,
Australian Government Department of Health. Available at: https://dev.pbs.gov.
au/content/schema/current/doc/html/elements/pbs_dpmq.html
Banzi, R., Gerardi, C., Bertele, V., and Garattini, S. (2015). Approvals of drugs
with uncertain beneﬁt-risk proﬁles in Europe. Eur. J. Int. Med. 26, 572–584.
doi: 10.1016/j.ejim.2015.08.008
Bjorkhem-Bergman, L., Andersen-Karlsson, E., Laing, R., Diogene, E.,
Melien, O., Jirlow, M., et al. (2013). Interface management of
pharmacotherapy. Joint hospital and primary care drug recommendations.
Eur. J. Clin. Pharmacol. 69(Suppl. 1), 73–78. doi: 10.1007/s00228-013-
1497-5
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., and Laing, R. (2009). Medicine
prices, availability, and aﬀordability in 36 developing and middle-income
countries: a secondary analysis. Lancet 373, 240–249. doi: 10.1016/S0140-
6736(08)61762-6
Cancer Care Ontario in Canada (CCO) (2017). Drug Formulary, CCO. Available
at: https://www.cancercareontario.ca/en/drugformulary/drugs/blinatumomab
Duong, M., Moles, R. J., Chaar, B., and Chen, T. F. (2015). World hospital
pharmacy research consortium(WHoPReC), essential medicines in a high
income country: essential to whom? PLoS One 10:e0143654. doi: 10.1371/
journal.pone.0143654
Erginel, E. (2014). European Commission Activities on Access to Medicines at the
Global Level, Global Health Policy Forum in Brussels, March 20th, Available
at: https://ec.europa.eu/health//sites/health/ﬁles/eu_world/docs/ev_20140320_
co4_en.pdf
Eriksen, J., Gustafsson, L. L., Ateva, K., Bastholm-Rahmner, P., Ovesjo,
M. L., Jirlow, M., et al. (2017). High adherence to the ‘wise list’
treatment recommendations in stockholm: a 15-year retrospective review of
a multifaceted approach promoting rational use of medicines. BMJ Open
7:e014345. doi: 10.1136/bmjopen-2016-014345
Eriksen, J., Ovesjo, M. L., Vallin, M., Juhasz-Haverinen, M., Andersen-Karlsson, E.,
Ateva, K., et al. (2018). Primary care physicians report high trust in
and usefulness of the Stockholm drug and therapeutic committee’s list of
recommended essential medicines (the ‘Wise List’). Eur. J. Clin. Pharmacol. 74,
131–138. doi: 10.1007/s00228-017-2354-8
Ermisch, M., Bucsics, A., Vella Bonanno, P., Arickx, F., Bybau, A., Bochenek, T.,
et al. (2016). Payers’ views of the changes arising through the possible adoption
of adaptive pathways. Front. Pharmacol. 7:305. doi: 10.3389/fphar.2016.00305
European Medicines Agency [EMA] (2018a). European Public Assessment Reports.
London: EMA. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
European Medicines Agency [EMA] (2018b). Conditional Marketing
Authorisation. London: EMA. Available at: http://www.ema.europa.eu/
ema/index.jsp?curl=pages/regulation/general/general_content_000009.jsp&
mid=WC0b01ac05809f843b
European Medicines Agency [EMA] (2017). Conditional Marketing Authorization
Report on Ten Years of Experience at the European Medicines Agency. London:
EMA.
Ferrario, A., Ara¯ja, D., Bochenek, T., Cˇatic´, T., Dankó, D., Dimitrova, M., et al.
(2017). The implementation of managed entry agreements in central and
eastern europe: ﬁndings and implications. PharmacoEconomics 35, 1271–1278.
doi: 10.1007/s40273-017-0559-4
Ferrario, A., and Kanavos, P. (2015). Dealing with uncertainty and high prices of
new medicines: a comparative analysis of the use of managed entry agreements
in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 124, 39–47.
doi: 10.1016/j.socscimed.2014.11.003
Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements
for Pharmaceuticals: The European Experience. Brussels: EMiNet.
Available at : http://eprints.lse.ac.uk/50513/
Garau, M., Towse, A., and Danzon, P. (2011). Pharmaceutical Pricing in Europe: Is
Differential Pricing a Win-Win Solution? London: Oﬃce of Health Economics.
Godman, B., Malmstrom, R. E., Diogene, E., Gray, A., Jayathissa, S., Timoney, A.,
et al. (2015). Are new models needed to optimize the utilization of new
medicines to sustain healthcare systems? Exp. Rev. Clin. Pharmacol. 8, 77–94.
doi: 10.1586/17512433.2015.990380
Godman, B., Paterson, K., Malmstrom, R. E., Selke, G., Fagot, J. P., and Mrak, J.
(2012). Improving the managed entry of new medicines: sharing experiences
across Europe. Exp. Rev. Pharmacoecon. Outcomes Res. 12, 439–441.
doi: 10.1586/erp.12.44
Godman, B., Wettermark, B., Hoﬀmann, M., Andersson, K., Haycox, A.,
and Gustafsson, L. L. (2009). Multifaceted national and regional drug
reforms and initiatives in ambulatory care in Sweden: global relevance.
Exp. Rev. Pharmacoecon. Outcomes Res. 9, 65–83. doi: 10.1586/14737167.
9.1.65
Godman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-
Madrazo, S., Berg, C., et al. (2014). Multiple policies to enhance prescribing
eﬃciency for established medicines in Europe with a particular focus on
demand-side measures: ﬁndings and future implications. Front. Pharmacol.
5:106. doi: 10.3389/fphar.2014.00106
Godman, B., Ortwijn, W., de Waure, C., Mosca, I., Puggina, A., Specchia,
M. L., et al. (2016). Links between Pharmaceutical R&D Models and Access
to Affordable Medicines. A Study for the ENVI COMMITTEE. Available at:
http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_
STU(2016)587321_EN.pdf
Gustafsson, L. L., Wettermark, B., Godman, B., Andersen-Karlsson, E.,
Bergman, U., Hasselstrom, J., et al. (2011). The ‘wise list’- a comprehensive
concept to select, communicate and achieve adherence to recommendations of
essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol.
108, 224–233. doi: 10.1111/j.1742-7843.2011.00682.x
Hogerzeil, H. V. (2004). The concept of essential medicines: lessons for rich
countries. BMJ 329, 1169–1172. doi: 10.1136/bmj.329.7475.1169
Korean Research-based Pharma Industry Association (KRPIA) (2016). Proposals
for Improving Patient Access to New Prescription Pharmaceuticals in Korea.
Seoul: KRPIA.
Kostic, M., Djakovic, L., Sujic, R., Godman, B., and Jankovic, S. M. (2017).
Inﬂammatory bowel diseases (crohn s disease and ulcerative colitis): cost of
treatment in serbia and the implications. Appl. Health Econ. Health Policy 15,
85–93. doi: 10.1007/s40258-016-0272-z
Lee, J. K., and Choi, W. S. (2008). Immunization policy in Korea. Korean J. Infect.
Dis. 40, 14–23. doi: 10.3947/ic.2008.40.1.14
Leopold, C., Mantel-Teeuwisse, A. K., Vogler, S., de Joncheere, K., Laing, R. O.,
and Leufkens, H. G. (2013). Is Europe still heading to a common price level
Frontiers in Pharmacology | www.frontiersin.org 8 September 2018 | Volume 9 | Article 938
Kwon et al. Conditional Approvals and Korea
for on-patent medicines? An exploratory study among 15 Western European
countries. Health Policy 112, 209–216. doi: 10.1016/j.healthpol.2013.08.012
Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G.,
and Laing, R. (2012). Diﬀerences in external price referencing in Europe: a
descriptive overview. Health Policy 104, 50–60. doi: 10.1016/j.healthpol.2011.
09.008
Malmstrom, R. E., Godman, B. B., Diogene, E., Baumgartel, C., Bennie, M.,
Bishop, I., et al. (2013). Dabigatran – A case history demonstrating the need for
comprehensive approaches to optimize the use of new drugs. Front. Pharmacol.
4:39. doi: 10.3389/fphar.2013.00039
Ministry of Health and Welfare in Korea (MOHW) (2013). High Cost Medicines
Like Target Anticancer Drug Will be Expansively Reimbursed. Seoul: MOHW.
Available at : http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_
ID=04&MENU_ID=0403&page=3&CONT_SEQ=290962&SEARCHKEY=
DEPT_NM&SEARCHVALUE
Ministry of Health & Welfare in Korea (MOHW) (2014). Pre-announcement
Legislation for Pharmaceutical Pricing Improvement. Seoul: MOHW. Available
at: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&
MENU_ID=0403&page=1&CONT_SEQ=315539&SEARCHKEY=TITLE&
SEARCHVALUE
Ministry of Health and Welfare (MOHW) (2015). Statistics for Reimbursable
Medicines. Seoul: MOHW.
Nakatani, H., and Sano, T. (2002). Development of vaccination policy in japan:
current issues and policy directions. Jpn. J. Infect. Dis. 55, 101–111.
Niëns, L. M., and Brouer, W. B. F. (2013). Measuring the aﬀordability of medicines:
importance and challenges. Health Policy 112, 45–52. doi: 10.1016/j.healthpol.
2013.05.018
Niëns, L. M., Van, de Poel E, Cameron, A., Ewen, M., Laing, R., and Brouwer, W. B.
(2012). Practical measurement of aﬀordability: an application to medicines.
Bull. World Health Organ. 90, 219–227. doi: 10.2471/BLT.10.084087
Ontrario Ministry of Health and Long-term care in Canada (2018). Enforcing Drug
Pricing Progress, Ontrario Ministry of Health and Long-term Care, Available
at: http://www.health.gov.on.ca/en/pro/programs/drugs/plan_reform_ods/
ensuring_enforc_drug_pricing.aspx
Organisation for Economic Co-operation and Development (OECD) (2008).
OECD Health Policy Studies Pharmaceutical Pricing Policies in (a) Global
Market. Paris: OECD.
Organisation for Economic Co-operation and Development [OECD] (2012).
Pharmaceutical Spending. Paris: OECD. Available at: https://data.oecd.org/
healthres/pharmaceutical-spending.htm
Paris, V., and Belloni, A. (2013). Value in Pharmaceutical Pricing. Available
at: http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-
pharmaceutical-pricing_5k43jc9v6knx-en
Patented Medicine Prices Review Board in Canada [PMPRB] (2015) Recognized
Sources for Foreign Price Verification and Formulas. Available at: http://www.
pmprb-cepmb.gc.ca/view.asp?ccid=1142
Patented Medicine Prices Review Board in Canada [PMPRB] (2017). Recognized
Sources for Foreign Price Verification and Formulas. Available at: http://www.
Pmprb-cepmb.gc.ca/view.asp?ccid=1298
Pauwels, K., Huys, I., Vogler, S., Casteels, M., and Simoens, S. (2017). Managed
entry agreements for oncology drugs: lessons from the european experience
to inform the future. Front. Pharmacol. 8:171. doi: 10.3389/fphar.2017.
00171
Pharmaceutical Management Agency in New Zealand [PHARMAC] (2018). Inside
the Pharmaceutical Schedule. Available at: https://www.pharmac.govt.nz/about/
your-guide-to-pharmac/factsheet-14-pharmaceutical-schedule
Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., et al. (2014).
Inequities in access to biologic and synthetic DMARDs across 46 European
countries. Ann. Rheumat. Dis. 73, 198–206. doi: 10.1136/annrheumdis-2012-
202603
Saitoh, A., and Okabe, N. (2012). Current issues with the immunization program
in Japan: can we ﬁll the “vaccine gap”? Vaccine 30, 4752–4756. doi: 10.1016/j.
vaccine.2012.04.026
Simoens, S., and Sinnaeve, P. R. (2014). Patient co-payment and adherence to
statins: a review and case studies. Cardiovasc. drugs Ther. 28, 99–109. doi:
10.1007/s10557-013-6497-2
Tang, C. W., Huang, S. H., Weng, K. P., Ger, L. P., and Hsieh, K. S. (2011). Patients’
views about the vaccination program in Taiwan. Pediat. Neonatol. 52, 98–102.
doi: 10.1016/j.pedneo.2011.02.009
The Federation of Japan Pharmaceutical Wholesalers Association [JPWA] (2014).
About VAT and pharmaceutical price’s policy. April, Available at: http://www.
jpwa.or.jp/jpwa/pdf/TaxReef_201404.pdf?20140423
Towse, A., Pistollato, M., Mestre-Ferrandiz, J., Khan, Z., Kaura, S., and Garrison, L.
(2015). European union pharmaceutical markets: a case for diﬀerential
pricing? Int. J. Econ. Bus. 22, 263–275. doi: 10.1080/13571516.2015.104
5747
Vella Bonanno, P., Ermisch, M., Godman, B., Martin, A. P., Van Den Bergh, J.,
Bezmelnitsyna, L., et al. (2017). Adaptive pathways: possible next steps for
payers in preparation for their potential implementation. Front. Pharmacol.
8:497. doi: 10.3389/fphar.2017.00497
Vogler, S., Kilpatrick, K., and Babar, Z. U. (2015). Analysis of medicine prices
in New Zealand and 16 European countries. Value Health 18, 484–492. doi:
10.1016/j.jval.2015.01.003
Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J., and Bucsics, A. (2012).
Discounts and rebates granted to public payers for medicines in European
countries. South Med. Rev. 5, 38–46.
World Health Organization (WHO) (2015). Access to New Medicines in Europe:
Technical Review of Policy Initiatives and Opportunities for Collaboration and
Research. Gneva: WHO. Available at: http://www.euro.who.int/__data/assets/
pdf_ﬁle/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.
pdf?ua=1
World Health Organization (WHO) (2010). Monitoring the Building Blocks of
Health Systems: A Handbook (of)Indicators and Their Measurement Strategies.
Geneva: WHO.
World Health Organization (WHO) (2011a). Marketing Authorization
of Pharmaceutical Products with Special Reference to Multisource
(Generic)Products: A Manual for National Medicines Regulatory Authorities
(NMRAs). Geneva: WHO.
World Health Organization (WHO) (2011b). WHO/HAI Project on Medicine
Prices and Availability Working Paper1: External Reference Pricing.
Geneva: WHO.
Young, K. E., Soussi, I., and Toumi, M. (2017). The perverse impact of external
reference pricing(ERP): a comparison of orphan drugs aﬀordability in 12
European countries. A call for policy change. J. Market Access Health Policy
5:1369817. doi: 10.1080/20016689.2017.1369817
Conflict of Interest Statement: HK is employed by the Korean National Health
Insurance Service.
The remaining authors declare that the research was conducted in the absence of
any commercial or ﬁnancial relationships that could be construed as a potential
conﬂict of interest.
Copyright © 2018 Kwon, Kim and Godman. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 9 September 2018 | Volume 9 | Article 938
